Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

Author:  

Publisher: Adis International

ISSN: 0114-9954

Source: Reactions Weekly, Vol.1, Iss.1430, 2012-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract